CytoMed Therapeutics (GDTC) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CytoMed Therapeutics (GDTC) has outperformed Lantern Pharma (LTRN) over the past year, losing 56.5% versus a loss of 81.9%. Lantern Pharma is the larger company by market cap ($12.1 million vs $10.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDTC | LTRN |
|---|---|---|
| Share price | $0.89 | $0.8127 |
| Market cap | $10.62M | $12.14M |
| 1-day change | -5.81% | -2.08% |
| YTD return | -29.22% | -72.61% |
| 1-year return | -56.46% | -81.92% |
| 5-year return | — | -91.71% |
| EPS (TTM) | $-0.23 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.68 | $4.68 |
| 52-week low | $0.68 | $0.7603 |
| Distance from 52-week high | -75.82% | -82.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +367.42% | +2053.32% |
| Average volume | 78.66K | 180.42K |
| Shares outstanding | 11.93M | 14.94M |
| Employees | 42 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GDTC has outperformed LTRN by 25.5 percentage points over the past year.
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
GDTC vs LTRN FAQ
Which is bigger, CytoMed Therapeutics or Lantern Pharma?
Lantern Pharma (LTRN) is larger, with a market capitalization of $12.14M compared with $10.62M for CytoMed Therapeutics (GDTC).
Which stock has performed better over the past year, GDTC or LTRN?
GDTC returned -56.46% over the past 12 months, compared with -81.92% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are CytoMed Therapeutics and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.